Cargando…

Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis

Mounting evidence points towards a pivotal role of gut microbiota in multiple sclerosis (MS) pathophysiology. Yet, whether disease-modifying treatments alter microbiota composition and whether microbiota shape treatment response and side-effects remain unclear. In this prospective observational pilo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Diebold, Martin, Meola, Marco, Purushothaman, Srinithi, Siewert, Lena K, Pössnecker, Elisabeth, Roloff, Tim, Lindberg, Raija LP, Kuhle, Jens, Kappos, Ludwig, Derfuss, Tobias, Egli, Adrian, Pröbstel, Anne-Katrin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9677991/ https://www.ncbi.nlm.nih.gov/pubmed/36398902 http://dx.doi.org/10.1080/19490976.2022.2147055

Ejemplares similares

Immunological Predictors of Dimethyl Fumarate‐Induced Lymphopenia
por: Diebold, Martin, et al.
Publicado: (2022)

Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis
por: Lorscheider, Johannes, et al.
Publicado: (2020)

High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis
por: Diebold, Martin, et al.
Publicado: (2022)

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

PARP-1 deregulation in multiple sclerosis
por: Meira, Maria, et al.
Publicado: (2019)

Dimethyl fumarate-associated lymphopenia: Risk factors and clinical significance
por: Longbrake, Erin E, et al.
Publicado: (2015)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
Publicado: (2018)

Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod
por: Nakhaei-Nejad, Maryam, et al.
Publicado: (2017)

Combination of Whole Genome Sequencing and Metagenomics for Microbiological Diagnostics
por: Purushothaman, Srinithi, et al.
Publicado: (2022)

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development
por: Meira, Maria, et al.
Publicado: (2016)

Dimethyl fumarate–induced lymphopenia in MS due to differential T-cell subset apoptosis
por: Ghadiri, Mahtab, et al.
Publicado: (2017)

Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis
por: Meira, Maria, et al.
Publicado: (2014)

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate
por: Sangurdekar, Dipen, et al.
Publicado: (2019)

CMV meningitis associated with dimethyl fumarate therapy-induced lymphopenia in a multiple sclerosis patient
por: Kogel, Ann-Kathrin, et al.
Publicado: (2021)

Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis
por: Lucchini, Matteo, et al.
Publicado: (2021)

Hepatitis E virus infections in patients with MS on oral disease-modifying treatment
por: Diebold, Martin, et al.
Publicado: (2019)

Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016)

Time course of lymphocyte repopulation after dimethyl fumarate-induced grade 3 lymphopenia: contribution of patient age
por: Briner, Myriam, et al.
Publicado: (2019)

Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Dimethyl fumarate treatment restrains the antioxidative capacity of T cells to control autoimmunity
por: Liebmann, Marie, et al.
Publicado: (2021)

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS
por: Zimmermann, Maria, et al.
Publicado: (2015)

Effect of dimethyl fumarate on lymphocytes in RRMS: Implications for clinical practice
por: Mehta, Devangi, et al.
Publicado: (2019)

Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study
por: Arnold, Douglas L., et al.
Publicado: (2014)

Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM
por: Giovannoni, Gavin, et al.
Publicado: (2016)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
por: Fischer-Barnicol, Bettina, et al.
Publicado: (2020)

Efficacy and Safety of Fingolimod in an Unselected Patient Population
por: Rasenack, Maria, et al.
Publicado: (2016)

Fumaric acid ester‐induced T‐cell lymphopenia in the real‐life treatment of psoriasis
por: Dickel, H., et al.
Publicado: (2019)

B Cells and Autoantibodies in Multiple Sclerosis
por: Pröbstel, Anne-Katrin, et al.
Publicado: (2015)

Dimethyl fumarate for ischemic stroke
por: Kunze, Reiner
Publicado: (2017)

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis
por: Kappos, L, et al.
Publicado: (2015)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Effects of Dimethyl Fumarate on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: Pooled Analysis Phase 3 DEFINE and CONFIRM Studies
por: Nakamura, Kunio, et al.
Publicado: (2022)

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)

Effects of dimethyl fumarate on neuroprotection and immunomodulation
por: Albrecht, Philipp, et al.
Publicado: (2012)

Dimethyl fumarate mitigates optic neuritis
por: Zyla, Katarzyna, et al.
Publicado: (2019)

Dimethyl fumarate transfer into human milk
por: Ciplea, Andrea I., et al.
Publicado: (2020)

Drug-Repurposing Strategy for Dimethyl Fumarate
por: Giunta, Salvatore, et al.
Publicado: (2023)

Antigen Extraction and B Cell Activation Enable Identification of Rare Membrane Antigen Specific Human B Cells
por: Zimmermann, Maria, et al.
Publicado: (2019)

Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years’ follow-up of DEFINE, CONFIRM, and ENDORSE
por: Gold, Ralf, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1r5i4ji1p4i3k6rqjfpk6j0bq6